• Journal of Plant Biotechnology
• /
• 제32권4호
• /
• pp.233-241
• /
• 2005

Plants have considerable advantages for the production of antigenic proteins because they provide an inexpensive source of protein and an easy administration of vaccine. Since a publication describing edible plant vaccine of HBsAg in 1992, a number of laboratories around the world have studied the use of plants as the bioreactor to produce antigenic proteins of human or animal pathogens. Over the last ten years, these works have been mainly focused on three major strategies for the production of antigenic proteins in plants: stable genetic transformation of either the nuclear or plastid genome, or transient expression in plants using viral vectors. As many antigenic proteins have been expressed in tobacco, also several laboratories have succeeded to express genes encoding antigenic proteins in other crop plants: potato, tomato, maize, carrot, soybean and spinach. At present many works for the production of edible plant vaccine against bacteria-mediated diseases have mostly performed the studies of enterotoxins and adhesion proteins. Also the development of new-type antigens (pili, flagella, surface protein, other enterotoxin and exotoxin etc.) is required for various targets and more efficacy to immunize against microorganism pathogens. Many works mostly studied in experimental animals had good results, and phase I clinical trial of LTB clearly indicated its immunogenic ability. On the other hand, edible plant vaccines have still problems remained to be solved. In addition to the accumulation of sufficient antigen in plants, human health, environment and agriculture regulation should be proven. Also oral tolerance, the physiological response to food antigens and commensal flora is the induction of a state of specific immunological unresponsiveness, needs to be addressed before plant-derived vaccine becomes a therapeutic option.

• 한국어병학회지
• /
• 제27권1호
• /
• pp.47-56
• /
• 2014

Propolis extracts는 다양한 성분으로 구성되어 있는 수지상의 혼합물로서 여러 약리작용을 보여주기 때문에 민간요법으로 널리 이용되어왔다. 특히 propolis extracts는 독성이 거의 없다는 장점 때문에 면역증강제재로서 활용가능성이 높게 평가되고 있다. 이에 본 실험에서는 대상으로 in vitro 및 in vivo상에서 propolis extracts가 양식넙치 면역반응에 미치는 영향을 조사하였다. In vitro상에서 propolis extracts가 PBL의 탐식능 및 NBT assay활성능에 미치는 영향을 조사 한 바 유효농도는 $50{\sim}150{\mu}g/ml$ 이었으며, 가장 활성이 높은 농도는 $100{\mu}g/ml$ 이었다. In vivo상에서 양식넙치에 propolis extracts를 단독 또는 S. iniae 불활화 균액과 혼합하여 어체에 투여 후에 면역반응에 미치는 영향을 조사하였다. Haematocrit치는 propolis extracts단독 및 vaccine과 혼합 처리 할때 유의적 차이를 보이지 않았다. 그렇지만, 혈청 lysozyme과 신장대식세포의 탐식능, 활성산소 환원능 및 항체가는 propolis extracts+vaccine 투여구에서 유의적으로 증가하였다. 이러한 결과들에 의하여 propolis extracts는 양식넙치에서 특이적 및 비특이적 면역증강작용이 우수하므로 향후 양식어류에 있어서 비특이적 면역증강 물질 및 adjuvant로 활용가능성이 기대되어진다.

• Journal of Microbiology
• /
• 제40권4호
• /
• pp.313-318
• /
• 2002

To perform the prophylactic study of a vaccine derived from human papillomavirus (HPV) using Balb/c mice, we produced virus like particles consisting of HPV capsid protein L1 which has been reported to induce significant humoral and cellular immunity using various animal model systems. In order to produce HPV16 VLPs, the cDNA of L1 capsid protein in HPV type 16, obtained by polymerase chain reaction, was inserted into yeast expression vector, YEG$\alpha$-HIR525 under the control of GAL10 promoter. The transformation of YEG$\alpha$-HPV16 L1 was performed into the yeast Saccharomyces cerevisiae Y2805 by the lithium acetate method and the yeast clone expressing the highest level of L1 capsid protein of human papillomavirus type 16 was selected by Western blot analysis using anti-HPV16 L1 antibody. The purification of HPV16 VLP has been performed by the ultracentrifugation and gel-filtration methods. To validate the vaccine efficacy of the purified HPV16 VLPs and investigate the properties of HPV16 VLPs to induce humoral immunity, ELISA assay was performed. A significantly increased production of anti-HPV16 VLP antibodies was observed in sera from immunized mice. The neutralization activity of antibodies in the sera from the vaccinated mice was demonstrated by a rapid and simple assay to detect hemagglutihation inhibition activity.

• Journal of Preventive Medicine and Public Health
• /
• 제40권4호
• /
• pp.291-296
• /
• 2007

Objectives : To explore the information sources and knowledge on infant vaccinations of pro-vaccination community members and anti-vaccination community members on the internet. Methods : An online survey of 245 parents from three pro-vaccination communities and 92 parents from one anti-vaccination community was conducted from June 7 to June 23, 2006. Results : Parents from pro-vaccination communities usually gained the information regarding vaccination efficacy and risk mainly from healthcare providers (49.8%) and mass media (47.7%). Pro-vaccination community members considered healthcare providers as the most credible sources of information on vaccination, whereas the anti-vaccination community members usually gained their information regarding vaccine efficiency and risk from Internet child-care cafes and online vaccination communities. Parents of the anti-vaccination community considered the internet as the most credible information source (77.6% for efficacy, 94.8% for risk). In addition, the major reason why anti-vaccination community members didn't vaccinate and, will not vaccinate, was concern about possible side effects of the vaccine. The knowledge level on infant vaccination, education and economic status was higher in the anti-vaccination community. Conclusions : On-line communities concerned with vaccination are getting popular. The influence of anti-vaccination parents on the Internet is expected to be high. The government and healthcare providers need to increase their efforts to improve the credibility of information about vaccination. Our findings suggest that online communication regarding vaccinations needs to be considered as a means to increase vaccination rates.

• 대한한의정보학회지
• /
• 제14권2호
• /
• pp.59-72
• /
• 2008

It makes study on the medical treatment and efficacy of Colostral milk. It based on the established treatises and books, in order to studying about the literature of colostral milk. It makes a through study on the medical treatment mechanism and efficacy of colostral milk, the results as fllows. 1. Colostral milk is some special things for baby newborn, and the other men and women of course. It is low in fat, and high in carbohydrates, protein, and antibodies to help keep your body healthy. Colostral milk is easy to digest, and it is low in volume, but high in concentrated nutrition for the newborn and men and women. 2. Colostral milk provides some of living cells which will defend babies against many harmful agents. The immune factors is much higher in colostral milk than in nature milk. Colostral milk works as a vaccine. It contains some quantities of an antibody called secretory immunoglobulin A Which is a important substance to the baby and men, 3. Colostral milk has a role to play in the baby's gastrointestinal tract. A newborn's intestines are permeable. The colostral milk makes the gastrointestinal tract in general. In addition, colostral milk contains a lot of leukocytes.

• 한국어병학회지
• /
• 제24권3호
• /
• pp.189-195
• /
• 2011

Starry flounder, which are recently increasingly cultured in Korea, are known to highly vulnerable to Streptococcus parauberis infection. Five groups of starry flounder (n=30 for each group) were vaccinated with S. parauberis formalin-killed whole cells by intraperitoneal injection at a final concentration of 0, 0.01, 0.1, 1 and 10 mg $fish^{-1}$. Specific antibody production of 1 and 10 mg $fish^{-1}$ administered groups significantly increased at four weeks post immunization. All vaccinated groups showed higher survival rates than a control group when five groups of fish were challenged with S. parauberis at a dose of $1.14{\times}10^4$ cfu $fish^{-1}$ and $1.14{\times}10^2$ cfu $fish^{-1}$, respectively. In particular, 0.1 or higher concentrations of formalin killed bacterial cells are able to confer the fish high protection against S. parauberis infection.

• 한국임상수의학회지
• /
• 제17권1호
• /
• pp.152-158
• /
• 2000

capsular polysaccharide(CPS), alpha toxin과 재조합 fibronectin binding protein (FnBP)으로 구성된 유방염 백신을 개발하여 야외효능실험을 수행하였다. 이 subunit 백신은 비유우 23두와 처녀우 20두를 대상으로 10개월동안 각각 수행되었다. 비유우는 매 3주간격으로 2회 백신접종을 하였으며 대조군은 PBS를 상유방림조절 주위에 피하주사하였다. 처녀우를 대상으로 한 실험에서는 분만 8주전부터 시작하여 매 3주간격으로 2회 비유우 백신접종부위와 동일하게 접종하였다. 접종후 비유우에서는 황색포도상구균에 의한 총유선내 감염율이 대조균에 비해 유의성있게 감소하였으며 (p<0.001) 처녀우에서도 총유선내 감염이 백신 접종균(1.6%)이 대조군(11.7%)에 비해 다음 비유기동안 유의성있게 낮았다. (p<0.001). 비유기동안 백신접종한 젖소의 체세포수는 변화가 없었으며 처녀우에서는 추가접종후 백신접종군에서 대조군의 체세포수에 비해 낮았지만 통계학적으로 유의성은 없었다(p>0.05). 본 실험결과 황색포도구균에 대한 유방염 아단위 백신은 비유우와 처녀우에서 체세포수를 증가시키지 않고 총 유선내 감염율을 낮추어주었다. 하지만 본 실험은 1군데의 목장을 대상으로 하였기 때문에 향후 대규모 목장을 대상으로 하는 유방염 백신의 야외효능실험이 심도있게 이루어져야 한다고 생각된다.

• 대한수의학회지
• /
• 제54권4호
• /
• pp.203-208
• /
• 2014

Bone marrow is a hematological and immunological organ that provides multiple immune cells, including B lymphocytes, and thus plays a critical role in the efficacy of vaccine. We previously demonstrated that Bordetella (B.) bronchiseptica antigen has high immunogenicity in spleen cells, a peripheral immune organ. In this study, we investigated the immunogenicity of B. bronchiseptica antigen in bone marrow cells, a central immune organ. B. bronchiseptica antigen increased the cellular activity of bone marrow cells and significantly enhanced the production of nitric oxide, IL-6, and TNF-${\alpha}$. Bone marrow cells primed with B. bronchiseptica antigen in vivo were harvested and stimulated with the same antigen in vitro. The stimulation of B. bronchiseptica antigen significantly increased the cellular activity and proliferation rate of the primed cells. B. bronchiseptica antigen also greatly induced the production of antigen-specific antibody in the primed cells. Taken together, the present study demonstrated that B. bronchiseptica antigen can stimulate bone marrow cells, a central immune organ, and recall the immune response of the primed bone marrow cells.

• The Korean Journal of Pain
• /
• 제26권3호
• /
• pp.242-248
• /
• 2013

Varicella (chickenpox) is a highly contagious airborne disease caused by primary infection with the varicella zoster virus (VZV). Following the resolution of chickenpox, the virus can remain dormant in the dorsal sensory and cranial ganglion for decades. Shingles (herpes zoster [HZ]) is a neurocutaneous disease caused by reactivation of latent VZV and may progress to postherpetic neuralgia (PHN), which is characterized by dermatomal pain persisting for more than 120 days after the onset of HZ rash, or "well-established PHN", which persist for more than 180 days. Vaccination with an attenuated form of VZV activates specific T-cell production, thereby avoiding viral reactivation and development of HZ. It has been demonstrated to reduce the occurrence by approximately 50-70%, the duration of pain of HZ, and the frequency of subsequent PHN in individuals aged ${\geq}50$ years in clinical studies. However, it has not proved efficacious in preventing repeat episodes of HZ and reducing the severity of PHN, nor has its long-term efficacy been demonstrated. The most frequent adverse reactions reported for HZ vaccination were injection site pain and/or swelling and headache. In addition, it should not be administrated to children, pregnant women, and immunocompromised persons or those allergic to neomycin or any component of the vaccine.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 제2회 추계심포지움
• /
• pp.61-67
• /
• 1994

One fundamental problem in developing an AIDS vaccine is antigenic variation of HIV. Despite a substantial induced immune response in gp120-immunized monkeys and humans, high titers of V3-directed type specific neutralizing antibodies may not be sufficient to neutralize continuously emerging new isolates. Several studies analyzing anti-gp120 antibodies in HIV-infected individuals have clearly indicated that most broadly neutralizing antibodies are directed to conformation-dependent epitopes. Therefore, it seems important to evaluate the potential efficacy of candidate gp120 vaccines at inducing such antibodies, that might be potentially protective against multiple HIV strains. One concern in the development of any recombinant protein as a vaccine is its stability when mixed with an adjuvant. This could be a particularly important factor for recombinant gp120, given the conformational nature of its major, broadly neutralizing, epitopes. We hypothesized that gp120 complexed with recombinant CD4 could stabilize the conformation-dependent epitopes and effectively deliver these epitopes to the immune system. In this study, a soluble gp120-CD4 complex in Syntex Adjuvant Formulation was tested in mice to analyze the anti-gp120 antibody response. With the aim of defining the fine specificity and neutalizing activities of the immune response, 17Mabs were generated and characterized. The studies indicate that the gp120-CD4 complex elicits neutralizing anti-gp120 antibodies, most of which are directed to the conformation dependent epitopes.